<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45-viruses-12-00520">
 <label>45.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mast</surname>
    <given-names>T.C.</given-names>
   </name>
   <name>
    <surname>Kierstead</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Gupta</surname>
    <given-names>S.B.</given-names>
   </name>
   <name>
    <surname>Nikas</surname>
    <given-names>A.A.</given-names>
   </name>
   <name>
    <surname>Kallas</surname>
    <given-names>E.G.</given-names>
   </name>
   <name>
    <surname>Novitsky</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Mbewe</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Pitisuttithum</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Schechter</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Vardas</surname>
    <given-names>E.</given-names>
   </name>
  </person-group>
  <article-title>International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials</article-title>
  <source>Vaccine</source>
  <year>2010</year>
  <volume>28</volume>
  <fpage>950</fpage>
  <lpage>957</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.145</pub-id>
  <pub-id pub-id-type="pmid">19925902</pub-id>
 </element-citation>
</ref>
